PharmaVentures is pleased to announce that it has acted as advisor to MedGenesis Therapeutix, Inc. (MedGenesis) in their recently announced agreement with Pfizer. MedGenesis´ unique therapeutic approach, which will be used in the clinical development of potential treatments for Parkinson´s disease, delivers GDNF (glial cell-derived neurotrophic factor) precisely to the regions of the brain where it is required via its convection enhanced delivery (CED) technology.
MedGenesis, a Canadian biotechnology company, has adapted the CED approach to enable unprecedented precision in delivery of drugs to predefined areas of the brain. Delivering GDNF to people with Parkinson´s disease in this way offers the possibility of treating the underlying disease rather than just the symptoms.
Adrian Dawkes, Vice President, who led the PharmaVentures team on the deal commented: "We are delighted to have worked with MedGenesis in partnering with one of the world´s leading pharmaceutical companies to complete development and commercialisation of the GDNF treatment. The CED technology could represent a paradigm shift in the treatment of Parkinson´s and many other neurological diseases".
Fintan Walton, Chief Executive, PharmaVentures, Ltd added: "PharmaVentures has a strong history in assisting companies in licensing but this agreement is quite special as it creates an exciting and unique partnership for the potential treatment of this debilitating disease ".
About PharmaVentures
PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. Our unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes us uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
Find out more www.pharmaventures.com
Our services include:
- M&A (divestments, mergers, acquisitions and strategic transactions)
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
- Licensing (in and out licensing)
- Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
Now in its 22nd year, PharmaVentures is based in Oxford, UK, and employs over 18 people.
